Full Press Release Details
EXPANDS EXECUTIVE TEAM WITH APPOINTMENT OF
Vos Brings Deep Experience in Market Development,
Products and Patient Advocacy
/ ACCESSWIRE /August 16, 2021 / Modular Medical, Inc. (OTCQB:MODD), a development-stage insulin pump company focused on providing
insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals
living with diabetes, today announced the expansion of its executive team with the appointment of Lynn O'Connor Vos as its
new Chief Executive Officer.
company's founder, industry veteran and renowned diabetes medical innovator, Paul DiPerna, will take on the role of Chairman,
President and Chief Technology Officer while continuing to drive platform development and R&D efforts.
In her new role as CEO, O'Connor
Vos will look to accelerate the company's effort to bring affordable insulin delivery
for greater adoption in the market by providing more individuals the opportunity
to achieve better diabetes health outcomes. In addition, she will focus on driving Modular Medical's initiatives for public/private/commercial
partnerships and advocacy, refining the patient experience and addressing the needs of the
3.5 million Americans who require intensive insulin therapy today.
Modular Medical, O'Connor Vos served as the President and CEO of the Muscular Dystrophy Association ("MDA")
for three years. She was instrumental in relaunching the organization's focus on innovations in science and care and successfully
built a pharmaceutical partnership practice. Prior, O'Connor Vos was a founding executive and CEO at Grey Healthcare Group,
a WPP-owned global healthcare communications firm serving a full range of pharma, biotech, surgical, diabetes, and diagnostic
companies with extensive work on healthcare launches. At WPP, she helped grow the agency from an independent domestic professional
firm into a top 10 award-winning global enterprise with fully integrated, multi-channel offerings. During her tenure, she led
the selection, evaluation, and negotiation of key deals to establish new digital, patient access and specialty care capabilities.
Additionally, O'Connor Vos has experience driving significant product launches and public-private partnerships for multiple
healthcare companies, including Text4Baby, a highly recognized national women's mobile health program.
a global healthcare business leader, with a broad range of omnichannel experience and an established launch track record that
will help Modular Medical as we continue to prepare for the commercial launch of our initial product in 2022," commented
DiPerna. "Additionally, Lynn's deep experience in tackling important healthcare challenges and establishing compelling
programs to address significant unmet needs will further help our company as we bring our novel approach of insulin delivery to
the market and outcomes for people living with diabetes."
is committed to making insulin pump technology a cornerstone of better control for all people living with diabetes, with a particular
focus on historically underserved communities.
extremely pleased and excited to join Modular Medical at this pivotal point of its development and commercialization efforts.
I look forward to working with the Modular Medical team in addressing areas of improving diabetes care by tackling the most significant
barriers: access and affordability, and making it easier for clinicians, caregivers and individuals to manage diabetes care,"
said O'Connor Vos. "I'm looking forward to engaging with the diabetes community again, after started my career
working on diabetes care programs, and believe there are meaningful opportunities to utilize innovative technology and therapies
like Modular Medical's to improve the consumer experience and health outcomes."
About Modular Medical,
Inc. (OTCQB:MODD) is a development-stage diabetes technology company based in San Diego CA. Working from an innovative set of
patented technologies, Modular seeks to expand access to high end diabetes technologies to the heretofore neglected majority of
the diabetes market who have been poorly served by the existing options which have been too expensive and complex to drive broad
adoption. Our strategy is to provide care at a level of cost and complexity designed not for "superusers" but for "the
rest of us". Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and world-class microfluidics
engineer. Mr. DiPerna was previously the founder (in 2005) of Tandem Diabetes (TNDM) and invented and designed their T:slim insulin
is available at https://modular-medical.com.
contains forward-looking statements regarding the expected timing of commercialization of the company's initial product.
Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties.
Actual results and trends may differ materially from those projected in any such forward-looking statements depending on a variety
of factors, including market conditions, the company's ability to commence commercialization of its initial product in a timely
fashion, and other risks identified in the company's most recent reports on Form 10-Q and Form 10-K filed with the SEC, as well
as other reports that Modular Medical files from time to time with the SEC. Modular Medical undertakes no obligation to update
publicly any forward-looking statement for any reason, except as required by law, even as new information becomes available or
other events occur in the future.
mentioned herein are the property of their respective owners.
Investor Relations Contact
Modular Medical, Inc.